Navigation Links
NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy
Date:9/21/2007

HIV virus, the immune system's fight against the infection, and the drugs administered to treat HIV. Painful HIV-DSP is characterized by significant pain in the feet and hands.

About NeurogesX, Inc.

NeurogesX (Nasdaq: NGSX) is a biopharmaceutical company focused on developing novel pain management therapies. Its initial focus is on chronic peripheral neuropathic pain, including PHN, painful HIV-DSP and painful diabetic neuropathy. NeurogesX' late stage product portfolio is led by its product candidate NGX-4010, a dermal patch designed to manage pain associated with peripheral neuropathic pain conditions, that the company believes offers significant advantages over other pain therapies. Three Phase 3 clinical trials with NGX-4010 have been completed and have met their primary endpoints, two in PHN and one in HIV-DSP.

Safe Harbor Statement

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). NeurogesX disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include, but are not limited to, statements relating to the successful completion of the C119 clinical trial with respect to NeurogesX' lead product candidate, NGX-4010, including the timing of announcement of results from such trial; filing for regulatory approval and the timing of such filings; the ability to obtain approval for and commercialize NGX-4010. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not lim
'/>"/>

SOURCE NeurogesX, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. NeurogesX Announces Presentation of Positive Phase 3 Clinical Data at the Second International Congress on Neuropathic Pain Meeting (NeuPSIG)
2. Lev Pharmaceuticals Completes Phase III Prophylaxis Trial of C1-Esterase Inhibitor for Hereditary Angioedema
3. Celsion Completes Enrollment in Phase I Liver Cancer Study
4. LANI completes Phase I in Japan and to commence Phase I in UK
5. Ace Biosciences, Ace393, the Worlds First Commercial Vaccine for Travellers Diarrhoea Caused by Campylobacter Successfully Completes Phase I Clinical Trials
6. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
7. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
8. MediQuest Concludes Confirmatory Phase III Study of Raynaud’s Therapy
9. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
10. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
11. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Sept. 30, 2014 Aileron Therapeutics, Inc. ... Global Markets Direct,s, ,Aileron Therapeutics, Inc. - ... of the Aileron Therapeutics, Inc.,s pharmaceutical research and ... on the current therapeutic developmental pipeline of Aileron ... stages, therapeutics assessment by drug target, mechanism of ...
(Date:9/30/2014)... , Sept. 30, 2014  Decision Resources Group finds that ... Australia , China , ... expand at a strong rate through 2023. Dental implant procedure volumes ... as patient awareness rises. Other key findings from Decision ... dental implant market: , Dental implant penetration: Penetration ...
(Date:9/30/2014)... 2014 According to ... by Product [Enzymes (Glycosyltransferase, Neuraminidase, Glycosidase), Instruments ... Application (Immunology, Oncology) & by End User ... MarketsandMarkets, provides a detailed overview of the ... trends, and strategies impacting the global glycomics ...
Breaking Medicine Technology:Aileron Therapeutics, Inc. - Product Pipeline Review - 2014 2Aileron Therapeutics, Inc. - Product Pipeline Review - 2014 3Asia Pacific Dental Implant Market Will Grow at a Strong Rate Through 2023 2Asia Pacific Dental Implant Market Will Grow at a Strong Rate Through 2023 3Glycobiology / Glycomics Market Worth $928.11 Million by 2019 2Glycobiology / Glycomics Market Worth $928.11 Million by 2019 3Glycobiology / Glycomics Market Worth $928.11 Million by 2019 4
... and Company) (NYSE: BDX ), a global medical technology company,announced today that ... Credit Suisse 2007 Healthcare Conference ... (ET), Lazard Capital ... November 27, 2007 - 9:00 a.m. (ET) A live webcast ...
... Golimumab Achieved Primary and Major Secondary Endpoints in ... Trial Completed to Date in Psoriatic Arthritis, ... arthritis,receiving monthly subcutaneous (SC) injections of golimumab (CNTO ... and skin,manifestations of the disease, according to findings ...
Cached Medicine Technology:Phase 3 Data Show New Anti-TNF, Golimumab, Significantly Improved Arthritis, Skin and Nail Manifestations in Patients with Psoriatic Arthritis 2Phase 3 Data Show New Anti-TNF, Golimumab, Significantly Improved Arthritis, Skin and Nail Manifestations in Patients with Psoriatic Arthritis 3Phase 3 Data Show New Anti-TNF, Golimumab, Significantly Improved Arthritis, Skin and Nail Manifestations in Patients with Psoriatic Arthritis 4Phase 3 Data Show New Anti-TNF, Golimumab, Significantly Improved Arthritis, Skin and Nail Manifestations in Patients with Psoriatic Arthritis 5Phase 3 Data Show New Anti-TNF, Golimumab, Significantly Improved Arthritis, Skin and Nail Manifestations in Patients with Psoriatic Arthritis 6Phase 3 Data Show New Anti-TNF, Golimumab, Significantly Improved Arthritis, Skin and Nail Manifestations in Patients with Psoriatic Arthritis 7Phase 3 Data Show New Anti-TNF, Golimumab, Significantly Improved Arthritis, Skin and Nail Manifestations in Patients with Psoriatic Arthritis 8
(Date:10/1/2014)... (PRWEB) October 01, 2014 ... networking and relationship-marketing firm, announced today the ... Executive® and Project of the Year Awards ... makers representing organizations in financial services, commercial, ... large-scale technology endeavors that address key issues ...
(Date:10/1/2014)... October 01, 2014 Beverly Hills licensed ... Mojas is celebrating 20 years of private practice in ... of people to achieve greater joy and fulfillment in ... of warning signs and suggestions for anyone who suspects ... explains: “Believe it or not, it’s not always ...
(Date:10/1/2014)... (PRWEB) October 01, 2014 NoteSwift Inc., ... EHR versions 10.0, 12.1 and 13.0. NoteSwift is the ... as commands to navigate and document clinical information at ... provider spends creating a patient note by more than ... of the major pain points providers state impedes EHR ...
(Date:10/1/2014)... in Bahir Dar, Ethiopia, at the occasion of ... gathered some 150 African and international leishmaniasis experts, ... safety and efficacy monitoring plan, carried out ... Sudan, Uganda, and Ethiopia, were presented to key ... to treatment of kala-azar with the combination of ...
(Date:10/1/2014)... 01, 2014 Dr. Saj Jivraj, one ... prosthodontists, is traveling to Chennai, India, tomorrow to speak ... 2 and 3. , Dr. Jivraj is founder of ... Oxnard, Calif., and one of the world’s foremost prosthodontists, ... replacement. He is speaking to the Indian Society of ...
Breaking Medicine News(10 mins):Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 2Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 3Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 4Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 5Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 6Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 7Health News:Prominent Beverly Hills Psychologist Dr. Kathleen Mojas Celebrating 20 Years in Private Practice Identifies Common Warning Signs That You May Be In a Toxic Relationship. 2Health News:Prominent Beverly Hills Psychologist Dr. Kathleen Mojas Celebrating 20 Years in Private Practice Identifies Common Warning Signs That You May Be In a Toxic Relationship. 3Health News:NoteSwift Joins Allscripts Developer Program 2Health News:NoteSwift Joins Allscripts Developer Program 3Health News:Results of large-scale roll out of combination treatment for kala-azar in Eastern Africa 2Health News:One of Woodland Hills’ Top Cosmetic Dentists Speaking to Indian Society of Oral Implantologists Tomorrow 2Health News:One of Woodland Hills’ Top Cosmetic Dentists Speaking to Indian Society of Oral Implantologists Tomorrow 3Health News:One of Woodland Hills’ Top Cosmetic Dentists Speaking to Indian Society of Oral Implantologists Tomorrow 4Health News:One of Woodland Hills’ Top Cosmetic Dentists Speaking to Indian Society of Oral Implantologists Tomorrow 5
... directs the University of Southern California Center for ... to evaluate robots as exercise coaches for adults of ... The effort, entitled "Robot Motivator: Towards Adaptive Health ... of virtual social characters on people,s motivation to exercise. ...
... , , - ... 41% from 31% in Q3 2008 , - Q3 2009 Operating ... 2009 Pre-tax Income Increases 168% from same period in 2008 , ... LWAY ), makers of the nutritious, probiotic dairy beverage called kefir, ...
... of this group with better preventive care, , THURSDAY, Nov. ... health measures can prolong lives, but only 25 percent of ... getting these recommended screenings, a new report shows. , Prepared ... and the American Medical Association, the report also lays out ...
... no more likely to have post-operative complications than those ... uterine fibroids, according to a study at Henry Ford ... fibroids, leaving the uterus intact and preserving the ability ... obese patient can present difficulties for the most experienced ...
... ... in Buffalo, NY, launched their revitalized and interactive website Monday, November 16, 2009. The ... . The project was initiated to provide users with an enhanced shopping and ordering ... (PRWEB) November 18, ...
... MELVILLE, N.Y., Nov. 19 Long Island IVF, a full ... patients achieve successful pregnancies, is now offering a new program ... treatment. Through this program and a partnership with In Vitro ... amount of money couples pay for their comprehensive treatment plans ...
Cached Medicine News:Health News:Lifeway Foods Reports Record 3rd Quarter 2009 Revenues and Earnings Results 2Health News:Lifeway Foods Reports Record 3rd Quarter 2009 Revenues and Earnings Results 3Health News:Lifeway Foods Reports Record 3rd Quarter 2009 Revenues and Earnings Results 4Health News:Lifeway Foods Reports Record 3rd Quarter 2009 Revenues and Earnings Results 5Health News:Lifeway Foods Reports Record 3rd Quarter 2009 Revenues and Earnings Results 6Health News:Lifeway Foods Reports Record 3rd Quarter 2009 Revenues and Earnings Results 7Health News:Lifeway Foods Reports Record 3rd Quarter 2009 Revenues and Earnings Results 8Health News: Too Few Older Adults Get Recommended Screenings 2Health News: Too Few Older Adults Get Recommended Screenings 3Health News:Patient's weight not linked to success of fibroid surgery 2Health News:Great Customer Service Just Got Better as Emedco Announces the Launch of their Completely Updated and Enhanced Website 2Health News:Great Customer Service Just Got Better as Emedco Announces the Launch of their Completely Updated and Enhanced Website 3Health News:Long Island IVF to Offer IVF Financial Share Program, Limiting Costs and Providing Refunds if IVF is Not Successful 2
... LH 755 simplifies and automates ... expert automation and advanced technologies ... reliable, accurate results every time. ... slide quality with its slide-on-slide ...
Kinetic and endpoint methods for the quantitative determination of creatinine in serum....
For the quantitative determination of creatine kinase-MB in serum. Kinetic Reaction measured at 340 nm. Linearity: 700 IU/L at 37C....
Intended for the quantitative determination of magnesium in serum. Wavelength: 340 nm. Linearity: 9.7 mg/dL (4 mmol/L). Two vials, dry powder reagents....
Medicine Products: